Overview

Real-World Betaseron Health Economic Outcomes Study for Relapsing Forms of Multiple Sclerosis

Status:
Completed
Trial end date:
2009-09-01
Target enrollment:
Participant gender:
Summary
A Web based real world observational study in Relapsing-Remitting Multiple Sclerosis (RRMS) population capturing outcomes reported by patients and by the physicians during 12 months after initiating or resuming Betaseron.
Details
Lead Sponsor:
Bayer
Treatments:
Interferon beta-1b
Interferon-beta
Interferons